Abstract
Background and aims: Merkel cell carcinoma (MCC) is a rare skin cancer with a high rate of recurrence. Serum antibodies to Merkel cell polyomavirus oncoprotein (AMERK) are present in 50% of patients and can be used to monitor for recurrence after achieving remission. It is expected that 90% 0f AMERK titers will normalized by one year after successful treatment and continue to fall subsequently. Our aim is to describe the longitudinal clinical course in patients with MCC and elevated AMERK levels despite having no evidence of disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
